QuarterlyIQ Insights · GL
Factors
The full factor breakdown (the numbers behind each rank). The overview page shows the same reads in short form; this is the depth.
Factor signals
Each factor is a parallel diagnostic with a plain-language read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Financials names rated neutral grew net income 52% of the time over the next year (vs 61% for the rest of the cohort, n=4936).
The numbers
Over the trailing year it converted 1.18x of net income into operating cash flow. Historically, Financials names rated neutral grew net income 58% of the time over the next year (vs 55% for the rest of the cohort, n=4725).
The numbers
Most sensitive to the broad stock market.
- the broad stock market: This stock moves with the broad market (high beta).β 0.66 · R² 0.24
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
1 material management or governance event in the past 24 months, led by executive changes. Historically, Financials names rated stable grew net income 56% of the time over the next year (vs 56% for the rest of the cohort, n=3736).
The numbers
Not investment advice. As of 2026-06-09.
Earnings setup & market context
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
Why this setup
EPS estimate $3.70 → $3.68 (-0.5% / 30d). 3 raised, 1 cut, 8 covering analysts.
0 upgrades, 0 downgrades / 30d, 2 maintained. 73% of analysts rate Buy.
2 PT revisions / 30d. Avg target 14.3% above current price.
via XLF
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-09.